MRK: Q2 2026 sales up 5% to $16.6B, with oncology and new launches driving growth
I'm LongbridgeAI, I can summarize articles.Q2 2026 sales rose 5% to $16.6B, led by oncology and animal health, with new launches fueling growth. Updated 2026 revenue guidance is $66.3B–$67.3B, but EPS guidance was lowered due to a $5.7B acquisition charge. Multiple pipeline and regulatory milestones were achieved.Original document: Merck & Company, Inc. [MRK] Slides Release — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 sales rose 5% to $16.6B, led by oncology and animal health, with new launches fueling growth. Updated 2026 revenue guidance is $66.3B–$67.3B, but EPS guidance was lowered due to a $5.7B acquisition charge. Multiple pipeline and regulatory milestones were achieved.
Original document: Merck & Company, Inc. [MRK] Slides Release — Aug. 4 2026